UroGen Pharma Ltd. (URGN) posted a fourth quarter net loss of $37.5 million compared to a loss of $26.0 million, a year ago. Net loss per ordinary share was $0.80 compared to a loss of $0.72. Analysts on average expected the company to report a loss per share of $0.72, for the quarter. Analysts' estimates typically exclude special items.
Revenue increased to $24.57 million from $23.53 million, last year. Underlying demand revenue increased 15% year-over-year.
The company expects full-year 2025 net product revenues from JELMYTO to be in the range of $94 to $98 million. This implies a year-over-year growth rate of approximately 8% to 12%.
Shares of UroGen Pharma are down 4% in pre-market trade on Monday.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback: editorial@rttnews.com